On September 15, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, reported that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021 (Press release, Revolution Medicines, SEP 15, 2021, View Source [SID1234587745]). Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference’s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company’s development-stage KRASG12C(ON) inhibitor, will each deliver a scientific presentation as part of the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Revolution Medicines’ participation in the 3rd Annual RAS-Targeted Drug Development Summit are as follows:

Presentations:

Title: Targeting KRASG12C(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors
Presenter: Bob Nichols, Ph.D., project lead for RMC-6291
Date: Wednesday, September 22, 2021
Time: 11:55 a.m. Eastern

Title: Combination Strategies to Defeat RAS-Addicted Cancers
Presenter: Jan Smith, Ph.D., senior vice president, biology
Date: Wednesday, September 22, 2021
Time: 2:00 p.m. Eastern

Panel Discussion:

Title: On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510
Moderator: Steve Kelsey, M.D., president, research and development
Date: Thursday, September 23, 2021
Time: 4:15 p.m. Eastern

Scientific Track:

Title: Validating Robust Combination Strategies
Chairperson: Steve Kelsey, M.D., president, research and development
Date/Time: Wednesday, September 22, 2021; 11:30 a.m. – 5:00 p.m. Eastern
Thursday, September 23, 2021; 11:00 a.m. – 12:30 p.m. Eastern

Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdevelopment.com/